Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg

Published 13/02/2017, 02:54
© Reuters. FILE PHOTO: The logo of French drugmaker Sanofi is seen in front of the company's headquarters in Paris
SASY
-
IPN
-

(Reuters) - Drugmaker Sanofi (PA:SASY) is close to selling some over-the-counter products to Ipsen SA (PA:IPN), in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.

The deal between the French drugmakers may be announced as early as Monday, Bloomberg reported, citing a person familiar with the matter. http://bloom.bg/2kAJLsp

Ipsen emerged as the preferred bidder after a competitive sale process involving other pharmaceutical companies, Bloomberg reported.

Both Ipsen and Sanofi could not be immediately reached for comments outside regular business hours.

Sanofi and German drugmaker Boehringer Ingelheim confirmed last month the closing of a $20 billion asset swap, under which Sanofi bought Boehringer's consumer health division, and the German firm purchased Merial animal health business.

© Reuters. FILE PHOTO: The logo of French drugmaker Sanofi is seen in front of the company's headquarters in Paris

($1 = 0.9418 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.